ACP
APLS

Acuta Capital Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Acuta Capital Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-76,100
Closed -$4.56M – 35
2023
Q4 		$4.56M Sell
76,100
-168,384
-69% -$8.54M 2.56% 18
2023
Q3 		$9.3M Sell
244,484
-53,112
-18% -$2.33M 6.23% 2
2023
Q2 		$27.1M Buy
297,596
+7,096
+2% +$612K 18.37% 1
2023
Q1 		$19.2M Buy
290,500
+73,000
+34% +$4.21M 14.12% 1
2022
Q4 		$11.2M Sell
217,500
-336,500
-61% -$17.8M 6.92% 3
2022
Q3 		$37.8M Hold
554,000
– – 16.29% 1
2022
Q2 		$25.1M Hold
554,000
– – 13.96% 1
2022
Q1 		$28.1M Buy
554,000
+19,000
+4% +$839K 13.15% 1
2021
Q4 		$25.3M Buy
535,000
+459,500
+609% +$18.1M 10.63% 2
2021
Q3 		$2.49M Sell
75,500
-85,000
-53% -$4.78M 0.88% 31
2021
Q2 		$10.1M Buy
160,500
+47,339
+42% +$2.44M 4.05% 4
2021
Q1 		$4.86M Sell
113,161
-53,893
-32% -$2.55M 1.75% 26
2020
Q4 		$9.55M Hold
167,054
– – 2.6% 14
2020
Q3 		$5.04M Sell
167,054
-22,946
-12% -$686K 1.37% 25
2020
Q2 		$6.21M Sell
190,000
-19,500
-9% -$626K 1.79% 24
2020
Q1 		$5.61M Buy
209,500
+22,000
+12% +$781K 2.72% 15
2019
Q4 		$5.74M Buy
+187,500
New +$5.19M 1.42% 20
2018
Q3 		– Sell
-168,000
Closed -$3.7M – 32
2018
Q2 		$3.7M Buy
+168,000
New +$3.86M 0.66% 29

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acuta Capital Partners's APLS Position: Q1 2024 in Review

Acuta Capital Partners sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 76,100 shares — an estimated $4.56M sold.

Acuta Capital Partners first reported a position in APLS in Q2 2018 and held it in 18 quarters. The position peaked at $37.8M in Q3 2022. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Acuta Capital Partners reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 76,100 Apellis Pharmaceuticals shares in Q1 2024, an estimated $4.56M.
  • Acuta Capital Partners first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 18 quarters.
  • Acuta Capital Partners's Apellis Pharmaceuticals position peaked at $37.8M in Q3 2022.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.